Risk assessment by myocardial perfusion imaging for coronary revascularization, medical therapy, and noncardiac surgery

Cardiology in Review

Volumn 11, Issue 2, 2003, Pages 60-72

  Papaioannou, Georgios I ^a   Heller, Gary V ^a,b  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b HARTFORD HOSPITAL   (United States)

Author keywords

Coronary artery disease; Myocardial perfusion imaging; Risk assessment

Indexed keywords

ACETYLSALICYLIC ACID; ANTIANGINA PECTORIS AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; NITRATE; PRAVASTATIN; PROPRANOLOL; THALLIUM 201;

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DYSLIPIDEMIA; EXERCISE TEST; HEART FAILURE; HEART MUSCLE REVASCULARIZATION; HEART SCINTISCANNING; HIGH RISK PATIENT; HUMAN; KIDNEY FAILURE; MORTALITY; PREOPERATIVE EVALUATION; RISK ASSESSMENT; RISK FACTOR; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TRANSLUMINAL CORONARY ANGIOPLASTY;

ALGORITHMS; CORONARY DISEASE; HUMANS; INTRAOPERATIVE COMPLICATIONS; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PREDICTIVE VALUE OF TESTS; PREOPERATIVE CARE; RISK ASSESSMENT; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0037347376     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.CRD.0000052100.88341.F9     Document Type: Article

References (88)

1. Gibbons RJ, Chatterjee K, Daley J, et al: ACC/AHA/ACPASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients with Chronic Stable Angina). Circulation 1999;99: 2829-2848.
2. Solomon AJ, Gersh BJ: Management of chronic stable angina: medical therapy, percutaneous transluminal coronary angioplasty, and coronary artery bypass surgery: lessons from the randomized trials. Ann Intern Med 1998; 128:216-223.
3. Yao SS, Rozanski A: Principal uses of myocardial perfusion scintigraphy in the management of patients with known or suspected coronary artery disease. Prog Cardiovasc Dis 2001;43:281-302.
4. Heo J, Thompson WO, Iskandrian AS: Prognostic implications of normal exercise thallium images. Am J Noninvas Cardiol 1987;1:209-212.
5. Pavin D, Delonca J, Siegenthaler M, et al: Long-term (10 years) prognostic value of a normal thallium-201 myocardial exercise scintigraphy in patients with coronary artery disease documented by angiography. Eur Heart J 1997;18: 69-77.
6. Raiker K, Sinusas AJ, Wackers FJT, et al: One-year prognosis of patients with normal planar or single-photon emission computed tomographic technetium 99m-labeled sestamibi exercise imaging. J Nucl Cardiol 1994;1:905-914.
7. National Center for Health Statistics: Vital Statistics of the United States, 1979: Mortality, part A. DHHS Publication No. (PHS) 84-1101. Washington, DC, US Government Printing Office, 1984; vol 2.
8. Brown KA, Rowen M: Prognostic value of a normal exercise myocardial perfusion imaging study in patients with angiographically significant coronary artery disease. Am J Cardiol 1993;71:865-867.
9. Schalet BD, Kegel JG, Heo J, et al: Prognostic implications of normal exercise SPECT thallium images in patients with strongly positive exercise electrocardiograms. Am J Cardiol 1993;72:1201-1203.
10. Ladenheim ML, Pollck BH, Rozanski A, et al: Extent and severity of myocardial hypoperfusion as predictors of prognosis in patients with suspected coronary disease. J Am Coll Cardiol 1986;7:464-471.
11. Brown K: Prognostic value of myocardial perfusion imaging: state of the art and new developments. J Nucl Cardiol 1996;3:516-537.
12. McClellan J, Travin M, Herman S, et al: Prognostic importance of scintigraphic left ventricular cavity dilatation during intravenous dipyridamole technetiun-99m sestamibi myocardial tomographic imaging in predicting coronary events. Am J Cardiol 1997;79:600-605.
13. Gill JB, Ruddy TD, Newell JB, et al: Prognostic importance of thallium uptake by the lungs during exercise in coronary artery disease. N Engl J Med 1987;317:1485-1489.
14. Acampa W, Cuocolo A, Sullo P, et al: Direct comparison of technetium 99m-sestamibi and technetium99m-tetrofosmin cardiac single photon emission computed tomography in patients with coronary artery disease. J Nucl Cardiol 1998;5:265-274.
15. Bavelaar-Croon C, Pauwels E, Van Der Wall E: Gated single-photon emission computed tomographic myocardial imaging: a new tool in clinical cardiology. Am Heart J 2001;141:383-390.
16. Borges-Neto S, Shaw L: The added value of simultaneous myocardial perfusion and left ventricular function. Curr Opin Cardiol 1999;14:460-463.
17. Sharir T, Germano G, Kavanagh PB, et al: Incremental prognostic value of post-stress left ventricular ejection fraction and volume by gated myocardial perfusion single photon emission computed tomography. Circulation 1999; 100:1035-1042.
18. Travin MI, Katz MS, Moulton AW, et al: Accuracy of dipyridamole SPECT imaging in identifying individual coronary stenosis and multivessel disease in women versus men. J Nucl Cardiol 2000;7:213-220.
19. Rithie J, Bateman T, Bonow R, et al: ACC/AHA guidelines for clinical use of cardiac radionuclide imaging: report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Radionuclide Imaging), developed in collaboration with the American Society of Nuclear Cardiology. J Am Coll Cardiol 1995;25:521-547.
20. Borges-Neto S, Watson JE, Miller MJ: Tc-99m-sestamibi cardiac SPECT imaging during coronary artery occlusion in humans: comparison with dipyridamole studies. Radiology 1996;198:751-754.
21. Hirzel HO, Nuesch K, Gruentzig AR, et al: Short and long term changes in myocardial perfusion after percutaneous transluminal coronary angioplasty assessed by thallium-201 exercise scintigraphy. Circulation 1981;63:1001-1007.
22. Hendel R: Assessment of revascularization. In: Zaret BL, Beller GA, eds. Nuclear Cardiology: State of the Art and Future Directions. 8th Edition. St. Louis, MO: Mosby; 1999:398-426.
23. Maseri A: The variable chronic atherosclerotic background. In: Maseri A. Ischemic Heart Disease. 1st Edition. New York, New York: Churchill Livingstone; 1995:193-235.
24. Beller G, Zaret B: Contributions of nuclear cardiology to diagnosis and prognosis of patients with coronary artery disease. Circulation 2000;101:1465-1478.
25. Smith SC, Dove JT, Jacobs AK, et al: ACC/AHA guidelines for percutaneous coronary interventions: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1993 Guidelines for Percutaneous Transluminal Coronary Angioplasty). J Am Coll Cardiol 2001;37:2215-2238.
26. Gibbons RS: American Society of Nuclear Cardiology project on myocardial perfusion imaging: measuring outcomes in response to emerging guidelines. (Editorial) J Nucl Cardiol 1996;3:436-442.
27. Topol EJ, Ellis SG, Delos M, et al: Analysis of coronary PTCA practice in the United States with an insurance-claims data base. Circulation 1993;87:1489-1497.
28. Pitt B, Waters D, Brown BW, et al, for the Atorvastatin versus Revascularization Treatment Investigators: Aggressive lipid lowering therapy compared with angioplasty in stable coronary artery disease. N Engl J Med 1999;341:70-76.
29. American Heart Association: 2001 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association; 2000.
30. Fitzgibbon GM, Kafka HP, Leach AJ, et al: Coronary artery by-pass fate and patient outcome: angiographic follow-up of 5,056 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 1996;28:616-626.
31. Greenberg BH, Hart R, Botvinick EH, et al: Thallium-201 myocardial perfusion scintigraphy to evaluate patients after coronary artery bypass surgery. Am J Cardiol 1978; 42:167-176.
32. Gibson RS, Watson DD, Taylor GJ, et al: Prospective assessment of regional myocardial perfusion before and after coronary revascularization surgery by quantitative thallium-201 scintigraphy. J Am Coll Cardiol 1983;1:804-815.
33. Nallamothu N, Johnson JH, Bagheri B, et al: Utility of stress single-photon emission computed tomography (SPECT) perfusion imaging in predicting outcome after coronary artery bypass grafting. Am J Cardiol 1997;80: 1517-1521.
34. Lakkis NM, Mahmarian JJ, Verani MS, et al: Exercise thallium-201 single photon emission computed tomography for evaluation of coronary artery bypass graft patency. Am J Cardiol 1995;76:107-111.
35. Pfisterer M, Emmenegger H, Schmitt HE, et al: Accuracy of serial myocardial perfusion scintigraphy with thallium-201 for prediction of graft patency early and late after coronary artery bypass surgery: a controlled prospective study. Circulation 1982;66:1017-1024.
36. Palmas W, Bingham S, Diamond GA, et al: Incremental prognostic value of exercise thallium-201 myocardial single photon emission computed tomography late after coronary artery bypass surgery. J Am Coll Cardiol 1995;25: 403-409.
37. Zellweger M, Lewin H, Shenghan L, et al: When to stress patients after coronary artery bypass surgery? risk stratification in patients early and late post-CABG using stress myocardial perfusion SPECT: implications of appropriate clinical strategies. J Am Coll Cardiol 2001;37:144-152.
38. Hecht HS, Shaw RE, Bruce RT, et al: Usefulness of tomographic thallium-201 imaging for detection of restenosis after percutaneous transluminal angioplasty. Am J Cardiol 1990;66:1314-1318.
39. DePuey EG: Myocardial perfusion imaging with thallium-201 to evaluate patients before and after percutaneous transluminal coronary angioplasty. Circulation 1991;84: 159-165.
40. Jain A, Mahmarian JJ, Borges-Neto S, et al: Clinical significance of perfusion defects by thallium-201 single photon emission tomography following oral dipyridamole early after coronary angioplasty. J Am Coll Cardiol 1988;11: 970-976.
41. Wijns W, Serruys PW, Reiber JH, et al: Early detection of restenosis after successful percutaneous transluminal coronary angioplasty by exercise-redistribution thallium scintigraphy. Am J Cardiol 1985;55:357-361.
42. Manyari DE, Knudtson M, Kloiber R, et al: Sequential thallium-210 myocardial perfusion studies after successful percutaneous transluminal coronary angioplasty: delayed resolution of exercise-induced scintigraphic abnormalities. Circulation 1988;77:86-95.
43. Hardoff R, Shefer A, Gips S, et al: Predicting late restenosis after coronary angioplasty by very early (12 to 24 H) thallium-201 scintigraphy: implications with regard to mechanisms of late coronary restenosis. J Am Coll Cardiol 1990;15:1486-1492.
44. Iskandrian AS, Lemlek J, Ogilby JD, et al: Early thallium imaging after percutaneous transluminal coronary angioplasty: tomographic evaluation during adenosine-induced coronary hyperemia. J Nucl Med 1992;33:2086-2089.
45. Mak KH, Belli G, Ellis SG, et al: Subacute stent thrombosis: evolving issues and current concepts. J Am Coll Cardiol 1996;27:494-503.
46. Baim D, Levine MJ, Leon MB, et al: Management of restenosis within the Palmaz-Schatz coronary stent (the US multicenter experience: the US Palmaz-Schatz stent investigators). Am J Cardiol 1993;71:364-366.
47. Gibbons RJ, Balady GJ, Beasley JW, et al: ACC/AHA guidelines for exercise testing: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Exercise Testing). J Am Coll Cardiol 1997;30:260-315.
48. Blumenthal R, Gregory C, Schulman S, et al: Medical therapy versus coronary angioplasty in stable coronary artery disease: a critical review of the literature. J Am Coll Cardiol 2000;36:668-673.
49. Mahmarian J, Moye L, Verani M, et al: High reproducibility of myocardial perfusion defects in patients undergoing serial exercise thallium-201 tomography. Am J Cardiol 1995;75:1116-1119.
50. Rainwater J, Steele P, Kirch D, et al: Effect of propranolol on myocardial perfusion images and exercise ejection fraction in men with coronary artery disease. Circulation 1982;65:77-81.
51. Steele P, Sklar J, Kirch D, et al: Thallium-201 myocardial imaging during maximal and submaximal exercise: comparison of submaximal exercise with propranolol. Am Heart J 1983;106:1353-1357.
52. Hockings B, Saltissi S, Croft DN, et al: Effect of beta adrenergic blockade on thallium-201 myocardial perfusion imaging. Br Heart J 1983;49:83-89.
53. Shehata A, Gillam L, Mascitelli V, et al: Impact of acute propranolol administration on dobutamine-induced myocardial ischemia as evaluated by myocardial perfusion imaging and echocardiography. Am J Cardiol 1997;80: 268-272.
54. Marie P, Danchin N, Branly F, et al: Effects of medical therapy on outcome assessment using exercise thallium-201 SPECT imaging. J Am Coll Cardiol 1999;34:113-121.
55. Stegaru B, Loose R, Keller H, et al: Effects of long-term treatment with 120 mg of sustained-release isosorbide dinitrate and 60 mg of sustained-release nifedipine on myocardial perfusion. Am J Cardiol 1988;61:74E-77E.
56. Mahmarian J, Fenimore N, Marks G, et al: Transdermal nitroglycerin patch therapy reduces the extent of exercise-induced myocardial ischemia: results of a double-blind, placebo-controlled trial using quantitative thallium-201 tomography. J Am Coll Cardiol 1994;24:25-32.
57. Billinger M, Seiler C, Fleisch M, et al: Do beta-adrenergic blocking agents increase coronary flow reserve? J Am Coll Cardiol 2001;38:1866-1871.
58. Flaker G, Warnica W, Sack F, et al: Pravastatin prevents clinical events in revascularized patients with average cholesterol concentrations. J Am Coll Cardiol 1999;34: 106-112.
59. Scandinavian Simvastatin Survival Group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994;344:1383-1389.
60. Rubins HB, Robins SJ, Collins D, et al: Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. N Engl J Med 1999;341:410-418.
61. Gould L, Martucci J, Goldberg D, et al: Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease. Circulation 1994;89:1530-1538.
62. Schwartz RG, Kalaria V, Mackin M, et al: Serial quantitative single photon emission computed tomography monitors improved myocardial perfusion accompanying cholesterol reduction therapy. (Absract) Circulation 1998; 98(Suppl):1-95.
63. Schwartz RG, Pearson T, Williford M, et al: Pravastatin improves stress induced radionuclide myocardial perfusion abnormalities by six months: Coronary Artery Disease Regression SPECT Monitoring Trial. J Am Coll Cardiol 2001;37(Suppl A):424A.
64. Schwartz RG, Pearson T: Can single photon emission tomography myocardial perfusion imaging monitor the potential benefit of aggressive treatment of hyperlipidemia? J Nucl Cardiol 1997;6:555-568.
65. Prasad A, Husain S, Quyyumi A, et al: Abnormal flow-mediated epicardial vasomotion in human coronary arteries is improved by angiotensin-converting enzyme inhibition. J Am Coll Cardiol 1999;33:796-804.
66. Schlaifer J, Wargovich T, O'Neil B, et al: Effects of quinapril on coronary blood flow in coronary artery disease patients with endothelial dysfunction. Am J Cardiol 1997;80:1594-1597.
67. Van Den Heuvel A, Dunselman P, Kingma T, et al: Reduction of exercise-induced myocardial ischemia during add on treatment with the angiotensin-converting enzyme inhibitor enalapril in patients with normal left ventricular function and optimal beta blockade. J Am Coll Cardiol 2001;37:470-474.
68. Gould L, Ornish D, Scherwitz L, et al: Changes in myocardial perfusion abnormalities by positron emission tomography after long-term, intense risk factor modification. JAMA 1995;274:894-901.
69. Parisi AF, Hartigan PM, Folland ED, for the ACME Investigators: Evaluation of exercise thallium-201 scintigraphy versus exercise electrocardiography in predicting survival outcomes and morbid cardiac events in patients with single- and double-vessel disease: findings from the Angioplasty Compared to Medicine Study. J Am Coll Cardiol 1997;30:1256-1263.
70. Dakik HA, Verani MS, He ZX, et al: Adenosine SPECT to assess anti-ischemic drug therapy versus coronary revascularization following myocardial infarction: a prospective randomized trial. (Abstract) J Nucl Cardiol 1997;4: S44.
71. National Center for Health Statistics: Advanced Data for Vital and Health Statistics, United States, 1988. DHHS Publication No. PHS 89-1232. Washington, DC, US Government Printing Office, 10-17, 66-7, 100-1, 1989.
72. Gibbons R, Antman M, Alpert J, et al: ACC/AHA Guideline update for perioperative cardiovascular evaluation for non-cardiac surgery: executive summary (Committee to Update the 1996 Guidelines on Perioperative Cardiovascular Evaluation for Non-Cardiac Surgery). J Am Coll Cardiol 2002;39:542-553.
73. Jeffrey CC, Kunsman J, Cullen DJ, et al: A prospective evaluation of cardiac risk index. Anesthesiology 1983;58: 462-464.
74. Brown KA: Prognostic value of thallium-201 myocardial perfusion imaging: a diagnostic tool comes of age. Circulation 1991;83:363-381.
75. Lette J, Waters D, Cerino M, et al: Preoperative coronary artery disease risk stratification based on dipyridamole imaging and a simple three step, three segment model for patients undergoing non-cardiac vascular surgery or major general surgery. Am J Cardiol 1992;69:1553-1558.
76. Brown KA, Rowen M: Extent of jeopardized viable myocardium determined by myocardial perfusion imaging best predicts perioperative cardiac events in patients undergoing non-cardiac surgery. J Am Coll Cardiol 1993;21:325-330.
77. Eagle KA, Coley CM, Newell JB, et al: Combining clinical and thallium data optimizes preoperative assessment of cardiac risk before major vascular surgery. Ann Int Med 1989;110:859-866.
78. Bonow RO: Assessment of myocardial viability with thallium-201. In: Zaret BL, Beller GA, eds. Nuclear Cardiology: State of the Art and Future Directions. 2nd Edition. St. Louis, MO: Mosby; 1999:503-512.
79. Dilsizian V, Rocco TP, Freedman NMT, et al: Enhanced detection of ischemic but viable myocardium by the reinjection of thallium after stress-redistribution imaging. N Engl J Med 1990;323:141-146.
80. Leppo JA: Preoperative cardiac risk assessment for noncardiac surgery. J Nucl Cardiol 1995;2:461-465.
81. Stratmann HG, Younis LT, Wittry MD, et al: Dipyridamole technesium-99m sestamibi myocardial tomography in patients evaluated for elective vascular surgery: prognostic value for perioperative and late cardiac events. Am Heart J 1996;131:923-929.
82. Stratmann HG, Younis LT, Wittry MD, et al: Dipyridamole technesium-99m sestamibi myocardial tomography for preoperative cardiac risk stratification prior to major or minor nonvascular surgery. Am Heart J 1996;132: 536-541.
83. Maunoury C, Stone DA, Chen CC, et al: Preoperative cardiac risk assessment with adenosine stress dual-isotope myocardial single photon emission computed tomography. Clin Cardiol 1996;19:488-490.
84. Van Damme H, Pierald L, Gillain D, et al: Cardiac risk assessment before vascular surgery: a prospective study comparing clinical evaluation, dobutamine stress echocardiography, and dobutamine Tc-99m-sestamibi tomoscintigraphy. Cardiovasc Surg 1997;5:54-64.
85. Hendel RC, Whitfield SS, Billegas BJ, et al: Prediction of late cardiac events by dipyridamole thallium imaging in patients undergoing elective vascular surgery. Am J Cardiol 1992;70:1243-1249.
86. Younis LT, Aguirre F, Byers S, et al: Perioperative and long-term prognostic value of intravenous dipyridamole thallium scintigraphy in patients with peripheral vascular disease. Am Heart J 1990;119:1287-1292.
87. Golden MA, Whittemore AD, Donaldson MC, et al: Selective evaluation and management of coronary artery disease in patients undergoing repair of abdominal aortic aneurysms. Ann Surg 1990;212:415-420.
88. Younis L, Stratmann H, Takase B, et al: Preoperative clinical assessment and dipyridamole thallium-201 scintigraphy for prediction and prevention of cardiac events in patients having major noncardiovascular surgery and known or suspected coronary artery disease. Am J Cardiol 1994;74:311-317.